Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors

John Edward Janik, William H. Sharfman, John W. Smitht, Dan L. Longo, Mario Sznol, Walter J. Urba, Robert Figlin, William C. Pierce, Ronald M. Bukowski, Gwen Fyfe, Arie Belldegrun

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background. Interleukin‐2 (IL‐2) recently was approved by the Food and Drug Administration for the treatment of renal cell cancer. It is effective in a small minority of patients, but no markers identify individuals likely to respond to treatment. Methods. Two polycythemic patients with erythropoietin‐producing renal cell cancer and three other polycythemic patients with renal cell cancer were treated with the combination of IL‐2 and alpha‐interferon (α‐IFN). Results. All five patients achieved a partial or complete remission. In both patients in which it was measured, the erythropoietin level decreased significantly with treatment, and the polycythemia resolved in all patients. Hypothyroidism developed in two patients, and transient hyperthyroidism developed in another. Conclusion. These results contrast with those achieved with IL‐2 alone or in combination with lymphokine‐activated killer cells, for which a 15% response rate was seen in patients with renal cell cancer and polycythemia. Although less than 5% of renal cell tumors produce erythropoietin, its production may identify a subset of individuals with renal cell cancer responsive to IL‐2 and α‐IFN.

Original languageEnglish (US)
Pages (from-to)2656-2659
Number of pages4
JournalCancer
Volume72
Issue number9
DOIs
StatePublished - Jan 1 1993

Fingerprint

Erythropoietin
Renal Cell Carcinoma
Neoplasms
Polycythemia
Hyperthyroidism
United States Food and Drug Administration
Hypothyroidism
Therapeutics
Kidney

Keywords

  • alpha‐interferon
  • erythropoietin
  • immunotherapy
  • interleukin‐2
  • renal cell cancer
  • tumor antigen
  • tumor marker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Janik, J. E., Sharfman, W. H., Smitht, J. W., Longo, D. L., Sznol, M., Urba, W. J., ... Belldegrun, A. (1993). Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors. Cancer, 72(9), 2656-2659. https://doi.org/10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A

Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors. / Janik, John Edward; Sharfman, William H.; Smitht, John W.; Longo, Dan L.; Sznol, Mario; Urba, Walter J.; Figlin, Robert; Pierce, William C.; Bukowski, Ronald M.; Fyfe, Gwen; Belldegrun, Arie.

In: Cancer, Vol. 72, No. 9, 01.01.1993, p. 2656-2659.

Research output: Contribution to journalArticle

Janik, JE, Sharfman, WH, Smitht, JW, Longo, DL, Sznol, M, Urba, WJ, Figlin, R, Pierce, WC, Bukowski, RM, Fyfe, G & Belldegrun, A 1993, 'Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors', Cancer, vol. 72, no. 9, pp. 2656-2659. https://doi.org/10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A
Janik, John Edward ; Sharfman, William H. ; Smitht, John W. ; Longo, Dan L. ; Sznol, Mario ; Urba, Walter J. ; Figlin, Robert ; Pierce, William C. ; Bukowski, Ronald M. ; Fyfe, Gwen ; Belldegrun, Arie. / Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors. In: Cancer. 1993 ; Vol. 72, No. 9. pp. 2656-2659.
@article{914b6a5cfe534ad6bdd1d94b88613dff,
title = "Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors",
abstract = "Background. Interleukin‐2 (IL‐2) recently was approved by the Food and Drug Administration for the treatment of renal cell cancer. It is effective in a small minority of patients, but no markers identify individuals likely to respond to treatment. Methods. Two polycythemic patients with erythropoietin‐producing renal cell cancer and three other polycythemic patients with renal cell cancer were treated with the combination of IL‐2 and alpha‐interferon (α‐IFN). Results. All five patients achieved a partial or complete remission. In both patients in which it was measured, the erythropoietin level decreased significantly with treatment, and the polycythemia resolved in all patients. Hypothyroidism developed in two patients, and transient hyperthyroidism developed in another. Conclusion. These results contrast with those achieved with IL‐2 alone or in combination with lymphokine‐activated killer cells, for which a 15{\%} response rate was seen in patients with renal cell cancer and polycythemia. Although less than 5{\%} of renal cell tumors produce erythropoietin, its production may identify a subset of individuals with renal cell cancer responsive to IL‐2 and α‐IFN.",
keywords = "alpha‐interferon, erythropoietin, immunotherapy, interleukin‐2, renal cell cancer, tumor antigen, tumor marker",
author = "Janik, {John Edward} and Sharfman, {William H.} and Smitht, {John W.} and Longo, {Dan L.} and Mario Sznol and Urba, {Walter J.} and Robert Figlin and Pierce, {William C.} and Bukowski, {Ronald M.} and Gwen Fyfe and Arie Belldegrun",
year = "1993",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A",
language = "English (US)",
volume = "72",
pages = "2656--2659",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors

AU - Janik, John Edward

AU - Sharfman, William H.

AU - Smitht, John W.

AU - Longo, Dan L.

AU - Sznol, Mario

AU - Urba, Walter J.

AU - Figlin, Robert

AU - Pierce, William C.

AU - Bukowski, Ronald M.

AU - Fyfe, Gwen

AU - Belldegrun, Arie

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background. Interleukin‐2 (IL‐2) recently was approved by the Food and Drug Administration for the treatment of renal cell cancer. It is effective in a small minority of patients, but no markers identify individuals likely to respond to treatment. Methods. Two polycythemic patients with erythropoietin‐producing renal cell cancer and three other polycythemic patients with renal cell cancer were treated with the combination of IL‐2 and alpha‐interferon (α‐IFN). Results. All five patients achieved a partial or complete remission. In both patients in which it was measured, the erythropoietin level decreased significantly with treatment, and the polycythemia resolved in all patients. Hypothyroidism developed in two patients, and transient hyperthyroidism developed in another. Conclusion. These results contrast with those achieved with IL‐2 alone or in combination with lymphokine‐activated killer cells, for which a 15% response rate was seen in patients with renal cell cancer and polycythemia. Although less than 5% of renal cell tumors produce erythropoietin, its production may identify a subset of individuals with renal cell cancer responsive to IL‐2 and α‐IFN.

AB - Background. Interleukin‐2 (IL‐2) recently was approved by the Food and Drug Administration for the treatment of renal cell cancer. It is effective in a small minority of patients, but no markers identify individuals likely to respond to treatment. Methods. Two polycythemic patients with erythropoietin‐producing renal cell cancer and three other polycythemic patients with renal cell cancer were treated with the combination of IL‐2 and alpha‐interferon (α‐IFN). Results. All five patients achieved a partial or complete remission. In both patients in which it was measured, the erythropoietin level decreased significantly with treatment, and the polycythemia resolved in all patients. Hypothyroidism developed in two patients, and transient hyperthyroidism developed in another. Conclusion. These results contrast with those achieved with IL‐2 alone or in combination with lymphokine‐activated killer cells, for which a 15% response rate was seen in patients with renal cell cancer and polycythemia. Although less than 5% of renal cell tumors produce erythropoietin, its production may identify a subset of individuals with renal cell cancer responsive to IL‐2 and α‐IFN.

KW - alpha‐interferon

KW - erythropoietin

KW - immunotherapy

KW - interleukin‐2

KW - renal cell cancer

KW - tumor antigen

KW - tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0027485448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027485448&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A

DO - 10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A

M3 - Article

VL - 72

SP - 2656

EP - 2659

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -